Biocryst Pharmaceuticals Inc (BCRX)
- Sector
- Biotechnology
- Last price
- $7.69
- As of
Kresmion compiles this page from BCRX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
BIOCRYST PHARMACEUTICALS INC (BCRX): 7 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-04.
See the full BCRX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for BCRX on one page. Preview it with sample data, then open it live with a free account.
Preview the BCRX dossierActive events for BCRX
- mediumEarnings above estimates
Q3-2026: Beat consensus by 63.4%, EPS $0.14 vs $0.0857 estimate
- high13F: funds added
4 tracked funds increased BCRX this 2026Q2, institutional consensus
- mediumEarnings above estimates
Q2-2026: Beat consensus by 148.1%, EPS $0.30 vs $0.1209 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +1236% to BCRX (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +76% to BCRX (2026Q2)
FREE, NO ACCOUNT
Every event on BCRX, as it fires
You are seeing 5 of 15 events recorded on BCRX since 2026-06-21.
The five above landed across 3 days. The other 10 were recorded on 2 other days. 8 of the 15 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
BCRX positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| TWO SIGMA INVESTMENTS, LP FundCUSIP 09058V103 · 2026Q2 | $67.8M | 0.05% |
| MILLENNIUM MANAGEMENT LLC FundCUSIP 09058V103 · 2026Q2 | $33.9M | 0.02% |
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 09058V103 · 2026Q2 | $25.3M | 0.03% |
| CITADEL ADVISORS LLC FundCUSIP 09058V103 · 2026Q2 | $17.6M | 0.01% |
| Bridgewater Associates, LP FundCUSIP 09058V103 · 2026Q2 | $4.9M | 0.02% |
| D. E. Shaw & Co., Inc. FundCUSIP 09058V103 · 2026Q2 | $4.1M | 0.00% |
| Point72 Asset Management, L.P. FundCUSIP 09058V103 · 2026Q2 | $2.6M | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, BCRX
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on BCRX
BCRX against its peers
BCRX's operating margin of 39.0% ranks in the 97th percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-03-31.
| Metric | BCRX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 875M USD | 50.0M USD | 90 | 14 |
| Gross margin | 97.8% | 87.7% | 83 | 8 |
| Operating margin | 39.0% | -783.5% | 97 | 14 |
| Net margin | 30.2% | -638.9% | 91 | 15 |
| Return on equity | n/a | -49.3% | n/a | 20 |
| P / E | 6.4x | n/a | n/a | 2 |
Peers (20): PVLA, LKFT, IMNM, VCEL, ZYME, SEPN, AUPH, VERA, RCUS, REPL, CLDX, NAMS, BHVN, PHVS, MESO, VIR, SRPT, RXRX, PGEN, AGIO. Left out: TRAX (no annual filing), ZLDPF (no annual filing), COAG (no annual filing), ADRX (no annual filing), GENB (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (BCRX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in BCRX on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on BCRX in the last 180 days.
Upstream: SEC EDGAR filings for BCRX
Kresmion, "BIOCRYST PHARMACEUTICALS INC (BCRX) institutional holdings and SEC filings", data as of 2026-11-04, https://kresmion.com/research/BCRX. Upstream data: SEC EDGAR filings for BCRX.
Link to this data (HTML):
<a href="https://kresmion.com/research/BCRX">BIOCRYST PHARMACEUTICALS INC (BCRX) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow BCRX on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to BCRX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.